According to a newly published market research report by 24LifeSciences, global Hepatocellular Carcinoma Drugs market was valued at USD 2.1 billion in 2024 and is projected to reach USD 3.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.3% during the forecast period 20252031. Hepatocellular Carcinoma (HCC), the most common primary liver cancer accounting for 90% of...

The global Keytruda Market was valued at USD 31.4 billion in 2025 and is projected to grow from USD 32.7 billion in 2026 to USD 25.0 billion by 2033, registering a CAGR of -3.8% from 2026 to 2033. While Keytruda (pembrolizumab) remains one of the most successful immunotherapy drugs globally, the market is expected to face headwinds over the forecast period due to patent expiration,...

According to a newly published market research report by 24LifeSciences, global bispecific T cell engager therapeutics market was valued at USD 5.8 billion in 2024 and is projected to reach USD 20.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 15.8% during the forecast period 20252032. Bispecific T cell engagers (BiTEs) represent a revolutionary class of...

According to a newly published market research report by 24LifeSciences, global bispecific T cell engager therapeutics market was valued at USD 5.8 billion in 2024 and is projected to reach USD 20.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 15.8% during the forecast period 20252032. Bispecific T cell engagers (BiTEs) represent a revolutionary class of...

According to a new report from Intel Market Research, the global Dual-Antibody ADC market was valued at USD 477 million in 2024 and is projected to reach USD 691 million by 2032, exhibiting a steady CAGR of 6.2% during the forecast period (2025–2032). This growth is driven by increasing cancer prevalence and demand for precision medicine, superior tumor targeting capabilities of...

According to a newly published market research report by 24LifeSciences, Global Lenvatinib Mesylate Capsules Market was valued at USD 1.3 billion in 2024 and is projected to reach USD 2.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period 20252032. Lenvatinib Mesylate, commercially known as Lenvima, is a multi-kinase inhibitor specifically...

The increasing burden of cancer and ophthalmic disorders is creating substantial demand for advanced therapeutic solutions worldwide. Anti-angiogenic therapies have become an important component of modern treatment strategies, particularly in oncology and retinal disease management. Continuous innovation in targeted therapies is further supporting industry expansion across developed and...

Tumor mice model market is witnessing sustained growth as oncology research intensifies and pharmaceutical companies seek more predictive preclinical platforms. Valued at USD 1.82 billion in 2024, the market is projected to reach USD 2.92 billion by 2031, expanding at a compound annual growth rate (CAGR) of 7.1% during the forecast period from 2025 to 2032. Discover Market Highlights –...

The United States Oncology Clinical Trials Market holds a dominant position globally, driven by a highly advanced healthcare ecosystem, strong presence of leading pharmaceutical and biotechnology companies, and significant investment in cancer research and development. The country continues to lead in the adoption of cutting-edge oncology therapies, including immunotherapy, targeted therapy,...

According to a newly published market research report by 24LifeSciences, the global unresectable hepatocellular carcinoma treatment market was valued at USD 1.8 billion in 2024 and is projected to reach USD 3.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.2% during the forecast period 20252032. Unresectable hepatocellular carcinoma (uHCC) refers to primary liver...